Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 1, 1999, Pages 71-76

  Di Giorgio, C ^a   Faraut Gambarelli, F ^c   Imbert, A ^c   Minodier, P ^b   Gasquet, M ^a   Dumon, H ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AMASTIGOTE; ARTICLE; CELL MEMBRANE POTENTIAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNOCOMPETENCE; INFANT; LEISHMANIA INFANTUM; PRESCHOOL CHILD; PROMASTIGOTE; PROTOZOAL INFECTION; RELAPSE; VISCERAL LEISHMANIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD, PRESCHOOL; DRUG RESISTANCE; FAT EMULSIONS, INTRAVENOUS; FLOW CYTOMETRY; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; INFANT; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MEMBRANE POTENTIALS; MONOCYTES;

EID: 0032816485     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.1.71     Document Type: Article

References (26)

1. Berman, J. D. (1997). Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 24, 684-703.
2. Herwaldt, B. L. & Berman, J. D. (1992). Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene 46, 296-306.
3. Faraut-Gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B., Marty, P., Michel, G. et al. (1997). In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 827-30.
4. Croft, S. L., Davidson, R. N. & Thornton, E. A. (1991). Liposomal amphotericin B in the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 111-18.
5. Davidson, R. N., Croft, S. L., Scott, A., Maini, M., Moody, A. H. & Bryceson, A. D. (1991). Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet 337, 1061-2.
6. Davidson, R. N. & Russo, R. (1994). Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clinical Infectious Diseases 19, 560.
7. Durand, R., Paul, M., Pratlong, F., Rivollet, D., Dubreuil-Lemaire, M. L., Houin, R. et al. (1998). Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 42, 2141-3.
8. Mbongo, N., Loiseau, P. M., Billion, M. A. & Robert-Gero, M. (1998). Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrobial Agents and Chemotherapy 42, 352-7.
9. Azas, N., Di Giorgio, C., Delmas, F., Gasquet, M. & Timon-David, P. (1997). Assessment of amphotericin B susceptibility in Leishmania infantum promastigotes by flow cytometric membrane potential assay. Cytometry 28, 165-8.
10. Peyron, F., Favel, A., Guiraud-Dauriac, H., El Mzibri, M., Chastin, C., Dumenil, G. et al. (1997). Evaluation of a flow cytofluorometric method for rapid determination of amphotericin B susceptibility of yeasts isolates. Antimicrobial Agents and Chemotherapy 41, 1537-40.
11. Ordonez, J. V. & Wehman, N. M. (1993). Rapid flow cytometric antibiotic susceptibility assay for Staphylococcus aureus. Cytometry 14, 811-18.
12. Ogunkolade, B. W., Colomb-Valet, I., Monjour, L., Rhodes-Feuillette, A., Abita, J. P. & Frommel, D. (1990). Interactions between the human monocytic leukaemia THP1 cell line and Old and New World species of Leishmania. Acta Tropica 47, 171-6.
13. Lazanas, M. C., Tsekes, G. A., Papandreou, S., Harhalakis, N., Scandali, A., Nikiforakis, E. et al. (1991). Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 7, 1018-19.
14. Sen Gupta, P. C. (1953). Chemotherapy of leishmanial diseases: a resume of recent researches. Indian Medical Gazette 88, 20-35.
15. Cascio, A., Gradoni, L., Scarlata, F., Gamiccia, M., Giordano S., Russo, R. et al. (1997). Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy. American Journal of Tropical Medicine and Hygiene 57, 75-8.
16. di Martino, L., Davidson, R. N., Giacchino, R., Scotti, S., Raimondi, F., Castagnola, E. et al. (1997). Treatment of visceral leishmaniasis in children with liposomal amphotericin B. Journal of Pediatrics 13, 272-7.
17. Matheron, S., Cabie, A., Parquin, F., Mayaud, C., Roux, P., Antoine, M. et al. (1992). Visceral leishmaniasis in HIV infection: unusual presentation with pleuropulmonary involvements, and effect of secondary prophylaxis. AIDS 6, 238-40.
18. Paul, M., Durand, R., Fessi, H., Rivollet, D., Houin, R., Astier, A. et al. (1997). Activity of a new liposomal formulation of amphotericin B against two strains of Leishmania infantum in a murine model. Antimicrobial Agents and Chemotherapy 41, 1731-4.
19. Mullen, A. B., Carter, K. C. & Baillie, A. J. (1997). Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 2089-92.
20. Coukell, A. J. & Brogden, R. N. (1998). Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55, 585-612.
21. Brajtburg, J., Powderly, W. G., Kobayashi, G. S. & Medoff, G. (1990). Amphotericin B: current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy 34, 183-8.
22. Sokol-Anderson, M., Sligh, J. E., Elberg, S., Brajtburg, J., Kobayashi, G. S. & Medoff, G. (1988). Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrobial Agents and Chemotherapy 32, 702-5.
23. Beggs, W. H. (1994). Physicochemical cell damage in relation to lethal amphotericin B action. Antimicrobial Agents and Chemotherapy 38, 363-4.
24. Ramos, H., Valdivieso, E., Gamargo, M., Dagger, F. & Cohen, B. E. (1996). Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions. Journal of Membrane Biology 152, 65-75.
25. Callahan, H. L., Portal, A. C., Devereaux, R. & Grogl, M. (1997). An axenic amastigote system for drug screening. Antimicrobial Agents and Chemotherapy 41, 818-22.
26. Mozaffarian, N., Berman, J. W. & Casadevall, A. (1997). Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrobial Agents and Chemotherapy 41, 1825-29.